摘要
中国是乙型肝炎病毒（HBV）的高流行区，HBV在非霍奇金淋巴瘤（NHL）的发生、发展中的作用越来越受到关注。NHL中HBV感染率高于其他实体瘤和普通人群。NHL治疗过程中常出现HBV再激活，已有研究提示HBV再激活增加了肝脏相关疾病的发生率和病死率。而在NHL治疗前预防性给予抗HBV药物可有效地减少HBV再激活。
[Objective] China is one of high hepatitis B virus （HBV）-epidemic areas. The role of HBV and non- Hodgkin lymphoma （NHL） has also recently been investigated. There is significantly higher prevalence rate of HBV infection among patients with NHL compared with other solid tumor and general population. HBV reactivation during chemotherapy is, however, a real concern. Several previous studies have reported increased risks of liver-related morbidity and mortality. The use of prophylactic anti-HBV drugs can effectively reduce the incidence and severity of hepatitis among HBV-infected patients who received chemotherapy for NHL.
出处
《白血病．淋巴瘤》
CAS
2009年第3期178-181,共4页
Journal of Leukemia & Lymphoma
